Columbia Laboratories is leveraging its rich heritage as a pharmaceutical research and development organization to become a leading women’s healthcare company. We will achieve this goal by increasing market share of our current products while developing new products for Columbia and our strategic partners.
We are focused on maximizing the return from our progesterone products in the United States through direct promotion to reproductive endocrinologists, obstetricians and gynecologists. To generate additional revenue from our products, we have entered into licensing agreements with marketing partners to sell our products in markets around the world and in U.S. markets that fall outside our strategic focus.
Developed in 1986, our products used the principles of bioadhesion to administer hormones and other compounds that are difficult to deliver.
CRINONE® 8% (progesterone gel), also sold as PROCHIEVE® 8% (progesterone gel), was introduced worldwide in 1997. Since then, it has been widely used by obstetricians, gynecologists, and fertility specialists to help women safely and effectively achieve and maintain pregnancy.
We are currently investigating the use of CRINONE to reduce the risk of preterm birth in women with a short cervix. We continue to explore new applications for our drug delivery systems. There are many promising products to come for the health of women in 2010…and beyond.
